A Closer Look at Multiple Sclerosis Treatments in 2014: BIIB, NVS, TEVA, SNY, RCPT
Several companies made notable advancements this year in treating multiple sclerosis (MS), a debilitating disease in which the body's immune system attacks the central nervous system.
MS affects an estimated 2.5 million people worldwide and 400,000 people in the United States. Of those patients, 85% are initially diagnosed with relapsing-remitting MS, which is characterized by alternating periods of relapses and remissions of the disease.
There is no cure for MS, and treatments have often caused terrible side effects, such as birth defects, cancer, and the risk of rare brain infections.
To better understand how much the market for MS treatments has evolved over the past year, let's take a closer look at Biogen Idec , Novartis , Teva Pharmaceutical , Sanofi , and newcomer Receptos .
Three promising plays: Biogen, Sanofi, and Novartis
Biogen, Sanofi, and Novartis are the most promising plays in the MS treatment market. Let's take a look at their most notable treatments.
Revenue (most recent quarter)
N/A (49% QOQ)
N/A (approved in the EU in Sept. 2013)
Source: Company quarterly reports.
While most MS treatments are injected or infused, Biogen's Tecfidera, Novartis' Gilenya, and Sanofi's Aubagio are oral drugs. This has led to some bullish forecasts for all three drugs -- analysts expect Tecfidera, Gilenya, and Aubagio to respectively hit annual peak sales of $3.8 billion, $2.1 billion, and $1.9 billion.
While all three drugs cause similar side effects, such as diarrhea and high liver blood tests, both Gilenya and Aubagio have worse serious risk profiles than Tecfidera.
Slow heart rate with first dose (monitoring required), swelling back of eye (macular edema), serious infection, potential birth defects.
Liver injury, potential birth defects, low white blood cell count, high blood potassium levels.
Low white blood count, potential birth defects.
That's not to say Gilenya and Aubagio don't have their advantages. Both are once-daily pills, while Tecfidera needs to be taken twice per day, with the dosage being doubled after the first week. However, Tecfidera's better safety profile has made it Wall Street's preferred drug.
Approved by the FDA in September 2010, Gilenya been on the market the longest. Looking into 2014, Novartis investors should check if Aubagio, which was approved in September 2012, and Tecfidera, which was approved last March, will threaten Gilenya's robust double-digit growth.
One play to avoid: Teva Pharmaceutical
Gains made by Biogen, Sanofi, and Novartis could sink Teva in 2014.
Last quarter, the injectable MS drug Copaxone generated $1.05 billion in revenue for Teva, accounting for 21% of the company's top line. However, sales of Copaxone are set to plunge next year, due to rising competition from the newer oral drugs and the expiration of a key patent in May 2014.
Mylan and Momenta Pharmaceuticals, which is partnered with Novartis subsidiary Sandoz, have already declared their intentions to launch generic Copaxone when Teva's patent expires.
A wild card: Receptos
Investors should keep an eye on Receptos, a new company that went public in May.
Receptos' lead drug candidate, RPC1063, is a new oral drug for relapsed MS and could eventually become the fourth approved drug for the indication, alongside Gilenya, Aubagio, and Tecfidera. RPC1063 is in phase 2/3 trials, with interim data expected next year. The drug is also being evaluated as a possible treatment for inflammatory bowel disease.
Since Receptos is a pre-revenue biotech with no marketed products, gauging its true market value is tough. However, investors have been fairly bullish on Receptos' prospects -- the stock has rallied more than 100% from its IPO price of $14.
The Foolish takeaway
In closing, 2014 could be a very promising year for MS treatments. Here are three key things investors should keep an eye on:
Sales growth of Tecfidera compared to Aubagio and Gilenya.
The effect of generic Copaxone on Teva's top- and bottom-line growth.
Interim data from Receptos' RPC1063, which could suggest its superiority or inferiority to available oral treatments.
These developments could significantly alter the market for MS treatments and exacerbate the decline of older injected and infused treatments in 2014.
The Motley Fool's Top Stock for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article A Closer Look at Multiple Sclerosis Treatments in 2014: BIIB, NVS, TEVA, SNY, RCPT originally appeared on Fool.com.
Fool contributor Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.